Compare Quest Diagnostics Inc (DGX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Sana Biotechnology Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Quest Diagnostics Inc is far larger — about 30.5× Sana Biotechnology Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Sana Biotechnology Inc for 23 Days on average.
| DGX | SANA | |
|---|---|---|
Market Cap | $25.48B | $836.71M |
Volume | 941,866 | 4,507,444 |
Sector | Health | Health |
52-Week High | $247.45 | $5.92 |
52-Week Low | $173.49 | $2.68 |
Typical Hold Time | 56 Days | 23 Days |
Enterprise Value | $31.23B | $749.96M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
